...
首页> 外文期刊>The Journal of Thoracic and Cardiovascular Surgery >Minimal-dose computed tomography is superior to chest x-ray for the follow-up and treatment of patients with resected lung cancer
【24h】

Minimal-dose computed tomography is superior to chest x-ray for the follow-up and treatment of patients with resected lung cancer

机译:最小剂量的计算机断层扫描优于胸X射线,用于切除肺癌患者的后续和治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: A minimal-dose computed tomography scan of the thorax (MnDCT) delivers a radiation dose comparable with a chest x-ray (CXR). We hypothesized that in patients with completely resected lung cancer, surveillance with MnDCT, when compared with CXR, leads to earlier detection and a higher rate of treatment of new or recurrent lung cancer. Methods: After lung cancer resection, patients prospectively were enrolled for surveillance with MnDCT and CXR at 3, 6, 12, 18, 24, 36, 48, and 60 months. Images were interpreted by different blinded radiologists. When new or recurrent cancer was suspected, standard-dose CT and/or a tissue biopsy were performed for confirmation. Results: Between 2007 and 2012, 271 patients were included and 1137 pairs of CXR and MnDCT were analyzed. MnDCT was more sensitive (94% vs 21%; P <.0001) and had a higher negative predictive value (99% vs 96%; P =.007) than CXR for the diagnosis of new or recurrent lung cancer. The prevalence of new or recurrent lung cancer was 23.2% (63 of 271), of whom 78% (49 of 63) had asymptomatic disease. The majority of asymptomatic patients (75%; 37 of 49) were treated with curative intent and had a median survival of 69 months. The remainder of patients received palliative treatment (24%; 12 of 49) and had a median survival of 25 months (P <.0001). Conclusions: After curative resection of lung cancer, MnDCT is superior to CXR for the detection of new or recurrent lung cancer. The majority of new or recurrent cancer was detected by MnDCT at an asymptomatic phase, allowing for curative treatment, leading to a long survival.
机译:目的:胸部(MNDCT)的最小剂量计算断层扫描(MNDCT)提供与胸部X射线(CXR)相当的辐射剂量。我们假设在完全切除肺癌的患者中,与CXR相比,患有MNDCT的监测,导致早期的检测和新的新或复发性肺癌的治疗率更高。方法:在肺癌切除后,患者预期注册了MnDCT和CXR的监测,3,6,12,18,24,36,48和60个月。图像被不同的盲化放射科医师解释。当怀疑新的或复发性癌症时,进行标准剂量CT和/或组织活检以进行确认。结果:2007年至2012年间,分析了271名患者,分析了1137对CXR和MNDCT。 MNDCT更敏感(94%vs 21%; P <.0001),比CXR具有更高的负预测值(99%与96%; p = .007),用于诊断新的或复发性肺癌。新的或经常性肺癌的患病率为23.2%(63分,共271例,共有63个)(49个中的49个)具有无症状的疾病。大多数无症状患者(75%; 49个中的37个)用治疗意图治疗,中位生存率为69个月。剩余的患者接受姑息治疗(24%; 49个中的12个),中位​​存活率为25个月(P <.0001)。结论:肺癌治疗切除后,MNDCT优于CXR,用于检测新的或复发性肺癌。 MNDCT在无症状期下检测到大多数新的或复发癌,允许治疗治疗,导致长期存活。

著录项

  • 来源
  • 作者单位

    Division of Thoracic Surgery University of Toronto Toronto ON Canada;

    Department of Radiology University of Toronto Toronto ON Canada;

    Division of Thoracic Surgery University of Toronto Toronto ON Canada;

    Department of Radiology University of Toronto Toronto ON Canada Division of Biostatistics;

    Division of Thoracic Surgery University of Toronto Toronto ON Canada;

    Division of Thoracic Surgery University of Toronto Toronto ON Canada;

    Division of Thoracic Surgery University of Toronto Toronto ON Canada;

    Division of Thoracic Surgery University of Toronto Toronto ON Canada;

    Division of Thoracic Surgery University of Toronto Toronto ON Canada;

    Division of Thoracic Surgery University of Toronto Toronto ON Canada;

    Division of Thoracic Surgery University of Toronto Toronto ON Canada;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 心脏、血管(循环系)疾病;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号